Updated Jul 16, 2026
Hohl Benjamin has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.76M.
Benjamin Hohl is the Chief Financial Officer of Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics. He has been involved in multiple SEC filings related to the company's financial activities.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 1.2K | $44.75 | $55K |
| 2026-06-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 3.4K | $43.86 | $149K |
| 2026-06-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 1.4K | $42.78 | $59K |
| 2026-06-22 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise | 6.0K | $2.48 | $15K |
| 2026-03-10 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 10.0K | $29.58 | $296K |
| 2026-02-18 | ELVN | Enliven Therapeutics, Inc. | A — Grant or award | 25.0K | $0.00 | |
| 2025-09-29 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 3.2K | $20.40 | $66K |
| 2025-09-29 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise | 3.2K | $2.48 | $8K |
| 2025-08-27 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 3.2K | $20.63 | $67K |
| 2025-08-27 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise | 3.2K | $2.48 | $8K |
| 2025-07-28 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 65 | $21.30 | $1K |
| 2025-07-28 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 3.2K | $20.45 | $65K |
| 2025-07-28 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise | 3.2K | $2.48 | $8K |
| 2025-07-10 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 1.0K | $22.66 | $23K |
| 2025-07-10 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise | 1.0K | $2.48 | $2K |
| 2025-06-27 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 198 | $21.66 | $4K |
| 2025-06-27 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 3.1K | $20.86 | $64K |
| 2025-06-27 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise | 3.2K | $2.48 | $8K |
| 2024-12-31 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 900 | $22.51 | $20K |
| 2024-12-31 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise [10b5-1] | 900 | $2.48 | $2K |
Benjamin Hohl is the Chief Financial Officer of Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics. He has been involved in multiple SEC filings related to the company's financial activities.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 23 open-market sales ($1.76M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Hohl Benjamin profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.